In addition, Walmart states that they “strongly disputes the allegations in these matters, and will continue to vigorously defend the company against any lawsuit not resolved through this settlement framework.” Thereby, avoiding admitting any wrongdoing the company may or may not have done. Additionally, the settlement referenced “objective data metrics showing Walmart dispensed on average materially fewer and less potent opioids per store than other major chain pharmacies and many independent pharmacies nationwide.”
The MDL is In re: National Prescription Opiate Litigation, case number 1:17-md-02804, in the U.S. District Court for the Northern District of Ohio.
